Search Results - "JANSSEN, Jeroen J. W. M"

Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia by Verhagen, Noor E, Koenderink, Jan B, Blijlevens, Nicole M. A, Janssen, Jeroen J. W. M, Russel, Frans G. M

“…Chronic myeloid leukemia (CML) is a hematologic neoplasm characterized by the expression of the BCR::ABL1 oncoprotein, a constitutively active tyrosine kinase,…”
Get full text

Two decades of targeted therapies in acute myeloid leukemia by Cucchi, David G. J., Polak, Tobias B., Ossenkoppele, Gert J., Uyl–De Groot, Carin A., Cloos, Jacqueline, Zweegman, Sonja, Janssen, Jeroen J. W. M.

“…Precision medicine is gaining importance in the treatment of acute myeloid leukemia (AML). Objectively reviewing past and current knowledge aids guiding future…”
Get full text

A Systematic Review of the Evidence of Hematopoietic Stem Cell Differentiation to Fibroblasts by Smilde, Bernard J, Botman, Esmée, de Vries, Teun J, de Vries, Ralph, Micha, Dimitra, Schoenmaker, Ton, Janssen, Jeroen J W M, Eekhoff, Elisabeth M W

“…Fibroblasts have an important role in the maintenance of the extracellular matrix of connective tissues by producing and remodelling extracellular matrix…”
Get full text

Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation by Bouwman, Linda, Eeltink, Corien M, Visser, Otto, Janssen, Jeroen J W M, Maaskant, Jolanda M

“…Medication non-adherence is associated with poor health outcomes and increased health care costs. Depending on definitions, reported non-adherence rates in…”
Get full text

Validation of the EUTOS long-term survival score in a recent independent cohort of “real world” CML patients by Geelen, Inge G. P., Sandin, Fredrik, Thielen, Noortje, Janssen, Jeroen J. W. M., Hoogendoorn, Mels, Visser, Otto, Cornelissen, Jan J., Hoglund, Martin, Westerweel, Peter E.

Get full text

Conditional relative survival among adult patients with chronic myeloid leukemia in the tyrosine kinase inhibitor era: a population-based study in the Netherlands by Ector, Geneviève I. C. G., Visser, Otto, Posthuma, Eduardus F. M., Westerweel, Peter E., Janssen, Jeroen J. W. M., Blijlevens, Nicole M. A., Dinmohamed, Avinash G.

Get full text

Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989–2017 by Ector, Geneviève I. C. G., Visser, Otto, Westerweel, Peter E., Janssen, Jeroen J. W. M., Blijlevens, Nicole M. A., Dinmohamed, Avinash G.

Get full text

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies by Griffioen, Mila S., de Leeuw, David C., Janssen, Jeroen J. W. M., Smit, Linda

“…Venetoclax is a BCL-2 inhibitor that effectively improves clinical outcomes in newly diagnosed, relapsed and refractory acute myeloid leukemia (AML) patients,…”
Get full text

Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment by de Leeuw, David C., Ossenkoppele, Gert J., Janssen, Jeroen J. W. M.

“…Purpose of Review Treatment of elderly patients with acute myeloid leukemia is a known challenge for hematologists due to patient diversity, heterogeneous…”
Get full text

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results by Mauro, Michael J., Hughes, Timothy P., Kim, Dong-Wook, Rea, Delphine, Cortes, Jorge E., Hochhaus, Andreas, Sasaki, Koji, Breccia, Massimo, Talpaz, Moshe, Ottmann, Oliver, Minami, Hironobu, Goh, Yeow Tee, DeAngelo, Daniel J., Heinrich, Michael C., Gómez-García de Soria, Valle, le Coutre, Philipp, Mahon, Francois-Xavier, Janssen, Jeroen J. W. M., Deininger, Michael, Shanmuganathan, Naranie, Geyer, Mark B., Cacciatore, Silvia, Polydoros, Fotis, Agrawal, Nithya, Hoch, Matthias, Lang, Fabian

“…Asciminib is approved for patients with Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia (CML-CP) who received ≥2 prior tyrosine kinase…”
Get full text

MRD Tailored Therapy in AML: What We Have Learned So Far by Ngai, Lok Lam, Kelder, Angèle, Janssen, Jeroen J W M, Ossenkoppele, Gert J, Cloos, Jacqueline

“…Acute myeloid leukemia (AML) is a heterogeneous clonal disease associated with a dismal survival, partly due to the frequent occurrence of relapse. Many…”
Get full text

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial by Efficace, Fabio, Mahon, Francois-Xavier, Richter, Johan, Piciocchi, Alfonso, Cipriani, Marta, Nicolini, Franck E., Mayer, Jiri, Zackova, Daniela, Janssen, Jeroen J. W. M., Panayiotidis, Panayiotis, Vestergaard, Hanne, Koskenvesa, Perttu, Almeida, Antonio, Hjorth-Hansen, Henrik, Martinez-Lopez, Joaquin, Olsson-Strömberg, Ulla, Hochhaus, Andreas, Berger, Marc G., Etienne, Gabriel, Klamova, Hana, Faber, Edgar, Rousselot, Philippe, Pfirrmann, Markus, Saussele, Susanne

“…Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free…”
Get full text

The wider perspective: twenty years of clinical trials in myelodysplastic syndromes by Duetz, Carolien, Cucchi, David G. J., Polak, Tobias B., Janssen, Jeroen J. W. M., Ossenkoppele, Gert J., Estey, Elihu H., Loosdrecht, Arjan A.

“…Summary Most patients with myelodysplastic syndromes (MDS) require therapeutic intervention. However, there are few approved treatments for MDS. To explore…”
Get full text

Dose selection of novel anticancer drugs: exposing the gap between selected and required doses by Hoog, Catharina J P Op ‘t, Mehra, Niven, Maliepaard, Marc, Bol, Kalijn, Gelderblom, Hans, Sonke, Gabe S, de Langen, Adrianus J, van de Donk, Niels W C J, Janssen, Jeroen J W M, Minnema, Monique C, van Erp, Nielka P, Boerrigter, Emmy

“…Historically, dose selection of anticancer drugs has mainly been based on establishing the maximum tolerated dose in phase 1 clinical trials with a traditional…”
Get full text

Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients by Kockerols, Camille, Valk, Peter J. M., Janssen, Jeroen J. W. M., Hogenbirk, Pauline, Cornelissen, Jan J., Saussele, Susanne, Spiess, Birgit, Perusini, Maria Agustina, Kim, Dennis, Westerweel, Peter E.

“…Precise and reliable predictive parameters to accurately identify chronic myeloid leukemia (CML) patients who can successfully discontinue their tyrosine…”
Get full text

Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia by Tettero, Jesse M., Heidinga, Maaike E., Mocking, Tim R., Fransen, Glenn, Kelder, Angèle, Scholten, Willemijn J., Snel, Alexander N., Ngai, Lok Lam, Bachas, Costa, van de Loosdrecht, Arjan A., Ossenkoppele, Gert J., de Leeuw, David C., Cloos, Jacqueline, Janssen, Jeroen J. W. M.

“…Measurable residual disease (MRD) measured in the bone marrow (BM) of acute myeloid leukemia (AML) patients after induction chemotherapy is an established…”
Get full text

The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018 by Maas, Carolien C. H. M., Klaveren, David, Ector, Geneviève I. C. G., Posthuma, Eduardus F. M., Visser, Otto, Westerweel, Peter E., Janssen, Jeroen J. W. M., Blijlevens, Nicole M. A., Dinmohamed, Avinash G.

“…Summary Studies on the conditional life expectancy of patients with chronic myeloid leukaemia (CML) are lacking. Using data from the Netherlands Cancer…”
Get full text

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes by Brunner, Andrew M., Esteve, Jordi, Porkka, Kimmo, Knapper, Steve, Traer, Elie, Scholl, Sebastian, Garcia‐Manero, Guillermo, Vey, Norbert, Wermke, Martin, Janssen, Jeroen J. W. M., Narayan, Rupa, Fleming, Shaun, Loo, Sun, Tovar, Natalia, Kontro, Mika, Ottmann, Oliver G., Naidu, Purushotham, Sun, Haiying, Han, May, White, Roisin, Zhang, Na, Mohammed, Anisa, Sabatos‐Peyton, Catherine A., Steensma, David P., Rinne, Mikael L., Borate, Uma M., Wei, Andrew H.

“…The safety and efficacy of sabatolimab, a novel immunotherapy targeting T‐cell immunoglobulin domain and mucin domain‐3 (TIM‐3), was assessed in combination…”
Get full text

Feasibility of and patients’ perspective on nilotinib dried blood spot self-sampling by Boons, Christel C. L. M., Timmers, Lonneke, Janssen, Jeroen J. W. M., Swart, Eleonora L., Hugtenburg, Jacqueline G., Hendrikse, N. Harry

“…Purpose To obtain insight into the feasibility of, and the patients’ perspective on, dried blood spot (DBS) self-sampling by patients with chronic myeloid…”
Get full text

TRough versus AUC Monitoring of cyclosporine: A randomized comparison of adverse drug reactions in adult allogeneic stem cell recipients (TRAM study) by Kuijvenhoven, Marianne A., Wilhelm, Abraham J., Meijer, Ellen, Janssen, Jeroen J. W. M., Swart, Eleonora L.

“…Objective To investigate the incidence and severity of adverse drug reactions of cyclosporine using AUC‐targeted therapeutic drug monitoring (TDM) compared to…”
Get full text